Tim joins Tissues Regenix most recently from KCI where he was Senior Director of Commercial and Sales Operations. He has over twenty five years of experience across many disciplines including contracting, revenue cycle, sales operations, finance and project management.
In the past, Tim has held positions with United Parcel Service, the Veteran's Administration and the United States Air Force. He has managed major organisational initiatives and has extensive experience with developing new business units and processes.
Tissue Regenix is currently establishing a new head office in San Antonio, to facilitate the next phase of its expansion which will see the company collaborating with more research and clinical partners to expand the range of treatments using the dCELL® process. Tim will be responsible for developing an agile infrastructure for the organisation that is capable of supporting the needs of the business and is customer-centric.
Tissue Regenix Wound Care Inc was established in November 2012 and has made a series of senior appointments from across the USA healthcare sector to build an experienced team to lead the company's development.
The first phase of this plan has seen Tissue Regenix, in June, sign a partnership with Community Tissue Services (CTS), the second largest tissue bank in the USA, to develop dCELL® dermis products to target the wound care market. Chronic wounds affect 6.5 million patients in the USA at a cost of care greater than $25bn, and the partnership between CTS and Tissue Regenix will allow the company's dCELL® technology to revolutionise treatment of patients. It follows a similar agreement signed in the UK with the NHSBT which is using Tissue Regenix' dCELL® technology to develop dermis woundcare treatments.
Tissue Regenix also has a long-standing research collaboration with Dr Alan Dardik, Associate Professor of Vascular Surgery at Yale University, to develop vascular patches; and with Professor Francisco da Costa from the Pontifical University of Panama to commercialise dCELL® Heart Valves and facilitate the Company's entry into the $1.0bn global tissue heart valve market.
|
The dCELL® process removes DNA and other cellular material from animal and human tissue, leaving an inert, acellular tissue scaffold which can be used to repair damaged organs and tissues, while dramatically cutting the risk of rejection by the patient's body.
Tissue Regenix is currently focusing on four product areas; woundcare, cardiac, vascular and orthopaedic.
distributed by |